ArticleJournal of clinical medicine2022
Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran).Blood advances · 2026Trial
- Personalized Anticoagulation in Cancer Patients: Current Evidence and Future Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Factor XI Inhibitors in Atrial Fibrillation: Insights and Implications from Recent Trials.Advances in therapy · 2026Review
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Advances in the Diagnosis and Management of High-Risk Cardiovascular Conditions: Biomarkers, Intracoronary Imaging, Artificial Intelligence, and Novel Anticoagulants.Journal of cardiovascular development and disease · 2026Review
- Balancing Safety and Efficacy: Factor XIa INHIBITORS vs. DOACs in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2025Review
- From Algorithms to Biomarkers: Toward Personalized Management of Venous Thromboembolism.Journal of clinical medicine · 2025Article
- Hemodynamics affects factor XI/XII anticoagulation efficacy in patient-derived left atrial models.Computer methods and programs in biomedicine · 2025Article
- Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis.Research and practice in thrombosis and haemostasis · 2025Article
- Anticoagulants in cirrhosis: main concerns.Nature reviews. Gastroenterology & hepatology · 2024Article
- Milvexian: An Oral, Bioavailable Factor XIa Inhibitor.Cardiology and therapy · 2024Review
- Overview of Venous Thromboembolism and Emerging Therapeutic Technologies Based on Nanocarriers-Mediated Drug Delivery Systems.Molecules (Basel, Switzerland) · 2024Review
- Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol stents under flow.Journal of thrombosis and haemostasis : JTH · 2024Article
- Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation.Nucleic acid therapeutics · 2024Review
- Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance.Hematology reports · 2024Review
- Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition.Current research in pharmacology and drug discovery · 2024Review
- Persistently High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis.Journal of clinical medicine · 2023Article
- Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.ACS pharmacology & translational science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleeding is the dominant adverse event of anticoagulation and often discourages many patients and physicians from starting treatment with anticoagulant drugs. The fact that factor (F)XI deficiency is associated with a mild bleeding phenotype and that FXI knockdown or inhibition in different animal models reduced the occurrence of thrombotic events in response to injury suggests that FXI is more important for the coagulation propagation and thrombotic process than for the overall hemostasis. The aim of this review is to summarize clinical pharmacology and evidence from phase 2 clinical trials on efficacy and safety of drugs directed against FXI for the treatment and prevention of thrombosis. Inhibition of FXI or FXIa has been proven to be effective in phase 2 studies at preventing venous thromboembolism (VTE) in patients undergoing total knee arthroplasty, or for prevention of major adverse vascular events in patients with end-stage kidney disease undergoing hemodialysis or as adjuncts to antiplatelet therapy for prevention of recurrent ischemic events in patients with acute myocardial infarction or non-cardioembolic stroke. Should the efficacy of FXI inhibitors as anticoagulant without impairing the hemostasis be proven in phase 3 randomized clinical trials, it would provide an innovative therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.